Davis Polk, Latham take lead as Roche sets sights on Genentech
Two US firms have snared lead roles on Swiss pharmaceutical group Roche’s $43.7bn (£21.88bn) bid for US drug giant Genentech. Davis Polk & Wardwell New York partners Arthur Golden, Chris Mayer and Peter Douglas are advising Roche, which acquired a 55.9 per cent stake in Genentech in 1990. While Latham & Watkins is yet to […]